Giordano, A., Avantaggiati, M.L., 1999. p300 and CBP: partners for life and death. J. Cell Physiol. 181, 218–230.

Grant, P.A., Duggan, L., Cote, J., Roberts, S.M., Brownell, J.E., Candau, R., Ohba, R., Owen-Hughes, T., Allis, C.D., Winston, F., Berger, S.L., Workman, J.L., 1997. Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: characterization of an Ada complex and the SAGA (Spt/Ada) complex. Genes Dev. 11, 1640–1650.

Harazono, A., Ema, M., Ogawa, Y., 1998. Evaluation of early embryonic loss induced by tributyltin chloride in rats: phase- and dose-dependent antifertility effects. Arch. Environ. Contam. Toxicol. 34, 94–99.

Horiguchi, T., Shiraishi, H., Shimizu, M., Morita, M., 1997. Effects of triphenyltin chloride and five other organotin compounds on the development of imposex in the rock shell Thais clavigera. Environ. Pollut. 95, 85–91.

Howe, L., Brown, C.E., Lechner, T., Workman, J.L., 1999. Histone acetyltransferase complexes and their link to transcription. Crit. Rev. Eukaryot. Gene Expr. 9, 231–243.

Ikeda, K., Steger, D.J., Eberharter, A., Workman, J.L., 1999. Activation domain-specific and general transcription stimulation by native histone acetyltransferase complexes. Mol. Cell. Biol. 19, 855–863.

Kannan, K., Senthikumar, K., Giesy, J.P., 1999. Occurrence of butyltin compounds in human blood. Environ. Sci. Technol. 33, 1776–1779.

Lo, S., Allera, A., Albers, P., Heimbrecht, J., Jantzen, E., Klingmuller, D., Steckelbroeck, S., 2003. Dithioerythritol (DTE) prevents inhibitory effects of triphenyltin (TPT) on the key enzymes of the human sex steroid hormone metabolism. J. Steroid Biochem. Mol. Biol. 84, 569–576.

Merkord, J., Weber, H., Kroning, G., Hennighausen, G., 2001. Repeated administration of a mild acute toxic dose of di-n-butyltin dichloride at intervals of 3 weeks induces severe lesions in pancreas and liver of rats. Hum. Exp. Toxicol. 20, 386–392.

Nakanishi, T., Kohroki, J., Suzuki, S., Ishizaki, J., Hiromori, Y., Takasuga, S., Itoh, N., Watanabe, Y., Utoguchi, N., Tanaka, K., 2002. Trialkyltin compounds enhance human CG secretion and aromatase activity in human placental choriocarcinoma cells. J. Clin. Endocrinol. Metab. 87, 2830–2837.

Nishihara, T., Nishikawa, J., Kanayama, T., Dakeyama, F., Saito, K., Imagawa, M., Takatori, S., Kitagawa, Y., Hori, S., Utsumi, H., 2000. Estrogenic Activities of 517 chemicals by yeast two-hybrid assay. J. Health Sci. 46, 282–298.

Nishikawa, J., Saito, K., Goto, J., Dakeyama, F., Matsuo, M., Nishihara, T., 1999. New screening methods for chemicals with hormonal activities using interaction of nuclear hormone receptor with coactivator. Toxicol. Appl. Pharmacol. 154, 76–83.

Ogryzko, V.V., Kotani, T., Zhang, X., Schiltz, R.L., Howard, T., Yang, X.J., Howard, B.H., Qin, J., Nakatani, Y., 1998. Histone-like TAFs within the PCAF histone acetylase complex. Cell 94, 35–44.

Osada, S., Takano, K., Nishihara, T., Suzuki, T., Muramatsu, M., Imagawa, M., 1995. CCAAT/enhancer-binding proteins α and β

interact with the silencer element in the promoter of glutathione S-transferase P gene during hepatocarcinogenesis. J. Biol. Chem. 270, 31288–31293.

Owen-Hughes, T., Utley, R.T., Steger, D.J., West, J.L., John, S., Cote, J., Havas, K.M., Workman, J.L. (Eds.), 1999. In: Chromatin Protocols., vol. 119. Humana Press, Totowa, NJ, pp. 319–331.

Rojas, J.R., Trievel, R.C., Zhou, J., Mo, Y., Li, X., Berger, S.L., Allis, C.D., Marmorstein, R., 1999. Structure of Tetrahymena GCN5 bound to coenzyme A and a histone H3 peptide. Nature 401, 93–98.

Seo, S.B., McNamara, P., Heo, S., Turner, A., Lane, W.S., Chakravarti, D., 2001. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 104, 119–130.

Spencer, T.E., Jenster, G., Burcin, M.M., Allis, C.D., Zhou, J., Mizzen, C.A., McKenna, N.J., Onate, S.A., Tsai, S.Y., Tsai, M.J., O'Malley, B.W., 1997. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389, 194–198.

Sterner, D.E., Berger, S.L., 2000. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64, 435–459.

Sutton, A., Shia, W.J., Band, D., Kaufman, P.D., Osada, S., Workman, J.L., Sternglanz, R., 2003. Sas4 and Sas5 are required for the histone acetyltransferase activity of Sas2 in the SAS complex. J. Biol. Chem. 278, 16887–16892.

Utley, R.T., Ikeda, K., Grant, P.A., Cote, J., Steger, D.J., Eberharter, A., John, S., Workman, J.L., 1998. Transcriptional activators direct histone acetyltransferase complexes to nucleosomes. Nature 394, 498–502.

Van der Kraak, G.J., Munkittrick, K.R., McMaster, M.E., Portt, C.B., Chang, J.P., 1992. Exposure to bleached kraft pulp mill effluent disrupts the pituitary-gonadal axis of white sucker at multiple sites. Toxicol. Appl. Pharmacol. 115, 224–233.

Wu, R.S., Panusz, H.T., Hatch, C.L., Bonner, W.M., 1986. Histones and their modifications. CRC Crit. Rev. Biochem. 20, 201–263.

Yamauchi, T., Yamauchi, J., Kuwata, T., Tamura, T., Yamashita, T., Bae, N., Westphal, H., Ozato, K., Nakatani, Y., 2000. Distinct but overlapping roles of histone acetylase PCAF and of the closely related PCAF-B/GCN5 in mouse embryogenesis. Proc. Natl. Acad. Sci. USA 97, 11303–11306.

Yan, Y., Barlev, N.A., Haley, R.H., Berger, S.L., Marmorstein, R., 2000. Crystal structure of yeast Esa1 suggests a unified mechanism for catalysis and substrate binding by histone acetyltransferases. Mol. Cell 6, 1195–1205.

Yao, T.P., Oh, S.P., Fuchs, M., Zhou, N.D., Ch'ng, L.E., Newsome, D., Bronson, R.T., Li, E., Livingston, D.M., Eckner, R., 1998. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93, 361–372.

Zoroddu, M.A., Schinocca, L., Kowalik-Jankowska, T., Kozlowski, H., Salnikow, K., Costa, M., 2002. Molecular mechanisms in nickel carcinogenesis: modeling Ni(II) binding site in histone H4. Environ. Health Perspect. 110 (Suppl. 5), 719–723.

Cloning and Characterization of a cDNA Encoding the Histone Acetyltransferase Monocytic Leukemia Zinc Finger Protein (MOZ) in the Rat

Kumiko Ohta, Shigehiro Osada, Jun-ichi Nishikawa, and Tsutomu Nishihara*

Laboratory of Environmental Biochemistry, Graduate School of Pharmaceutical Sciences, Osaka University, 1–6 Yamada-Oka, Suita, Osaka 565–0871, Japan

Many DNA-binding transcription factors require coactivators for their function. Some of these coactivators have histone acetyltransferase (HAT) activity, which is important for transcription from chromatin template. We cloned a cDNA encoding the rat homolog of monocytic leukemia zinc finger protein (MOZ), a member of the MYST (MOZ, Ybf2/Sas3, Sas2, and Tip60) acetyltransferase family. Rat MOZ (rnMOZ) encoded 1998 amino acids and was composed of 16 exons. Comparison of the rnMOZ and human MOZ amino acid sequences revealed 89% identity over the whole sequence and 100% identity in the MYST region, which is essential for HAT activity. Further, we identified physical interaction between rnMOZ and basic leucine zipper (bZIP)-type DNA-binding proteins, including c-Jun and CCAAT/enhancer binding proteins. This finding suggests that MOZ may function in multiple cellular processes through various bZIP-type transcription factors.

Key words —— histone acetyltransferase, monocytic leukemia zinc finger protein, transcription, c-Jun, CCAAT/ enhancer binding protein, basic region leucine zipper family

INTRODUCTION

Transcription of eukaryotic genes is controlled by various regulatory elements, termed promoters, enhancers, and silencers. These elements are recognized by sequence-specific DNA-binding proteins.[1]

A virtual explosion of information in the field of eukaryotic gene regulation has revealed that many DNA-binding transcription factors require coactivators that have histone acetyltransferase (HAT) activity.[2] Active chromatin has been associated with hyperacetylation of histones, binding of transcriptional regulators, and active transcription.[3]

Some HATs in multiple-protein complexes are recruited by DNA-binding transcription factors to chromatin, whereas others are physically associated with DNA-binding proteins. Monocytic leukemia zinc finger protein (MOZ) is a member of the MYST (MOZ, Ybf2/SAS3, SAS2, and TIP60) family of HATs, which play key roles in various nuclear functions[2] and frequently are rearranged in leukemia.[2,4] Only human MOZ (hsMOZ) cDNA had been cloned previously.[5] Although the MOZ complex has been identified,[4] physical interaction between MOZ and DNA-binding transcription factors has not yet been reported. Candidates for associating factors include the basic region leucine zipper (bZIP) proteins, which are a large class of transcription factors including c-Jun, c-Fos, and CCAAT/enhancer binding proteins (C/EBPs) that are crucial for cell proliferation, cell differentiation, and cancer development.[6]

We cloned rat MOZ (rnMOZ) cDNA and showed that rnMOZ interacted with various bZIP-type transcription factors.

MATERIALS AND METHODS

Cloning of rnMOZ cDNA and Plasmid Construction —— All animal care and handling procedures were approved by the animal care and use committee of Osaka University. Total RNA was prepared from Wister rat liver by using TriZol reagent

*To whom correspondence should be addressed: Laboratory of Environmental Biochemistry, Graduate School of Pharmaceutical Sciences, Osaka University, 1–6 Yamada-Oka, Suita, Osaka 565–0871, Japan. Tel.: +81-6-6879-8240; Fax: +81-6-6879-8244; E-mail: nisihara@phs.osaka-u.ac.jp

Table 1. PCR Condition

Amplifed Position	Primer Sequence	Denature	Annealing	Extension	Cycles
1-993	5'-ATAGAATTCATGGTAAAACTCGCTAACC-3'				
	5'-AAGCGGCCGCGTTAATAGCGCCGTTTTATC-3'	94 °C, 1 min	54°C, 1 min	72°C, 1 min	36
804-2336	5'-TCGCGATCAAGGCAAAAACG-3'				
	5'-ACTATGACTGGAGTCCAGCG-3'	94 °C, 1 min	54°C, 1 min	72°C, 2 min	43
1969-3524	5'-GGCAGGTTTCTCATCGATTTCA-3'				
	5'-TTAAATCCTGGTTTCCGTCCAGG-3'	94 °C, 1 min	54°C, 1 min	72°C, 2 min	40
3271-4722	5'-AAGACATCCTTAGGTGTCAGGCTT-3'				
	5'-GTTATTCCCACAAATACTGCTG-3'	94 °C, 1 min	56°C, 1 min	72°C, 1.5 min	40
4576-5386	5'-AAATGGATGTGCCTTCCGTATC-3'				
	5'-AACGGCTAAGGGATGAGATGGA-3'	94 °C, 1 min	56°C, 1 min	72°C, 2 min	40
4576-5997	5'-AAATGGATGTGCCTTCCGTATC-3'				
	5'-TTTGCGGCCGCATCATCTTCTCATGTAAGG-3'	94 °C, 1 min	54°C, 1 min	72°C, 2 min	40
5100-5997	5'-ATTGAATTCATGAACAACAGCTTCACTGC-3'				
	5'-TTTGCGGCCGCATCATCTTCTCATGTAAGG-3'	94 °C, 1 min	56°C, 1 min	72°C, 1 min	36

(Invitrogen, Carlsbad, CA, U.S.A.) according to the manufacturer's recommendations. The open reading frame (ORF) of rnMOZ was amplified by reverse transcriptase-polymerase chain reaction (RT-PCR); PCR conditions are found in Table 1. The seven fragments we obtained were subcloned into pBluescript KS (Stratagene, La Jolla, CA, U.S.A.) and sequenced. To subclone the full-length rnMOZ ORF into the EcoRI-NotI site of the mammalian expression vector pCI (Promega, Madison, WI, U.S.A.), cDNA fragments were assembled using suitable internal restriction sites. Glutathione S-transferase (GST)-fused rat c-Jun constructs were generated by PCR from pRJ101[7] (kindly provided Dr. Masayoshi Imagawa of Nagoya City University). GST-c-Jun [contains full-length (FL) Jun], GST-c-Jun [contains the Jun transactivation domain (AD)], and GST-c-Jun [includes the DNA-binding domain (DBD) of Jun] were constructed by inserting fragments corresponding to amino acid residues 1-334, 1-146, and 257-334, respectively, into the BamHI-XhoI site of pGEX4T-1 (Amersham Biosciences, Piscataway, NJ, U.S.A.). All fragments amplified by PCR were verified by DNA sequencing. GST-fused C/EBPα and C/EBPβ expression plasmids[8] were kindly provided by Dr. Robert Hache of Ottawa University.

GST Pull-Down Assay —— GST fusion proteins were expressed in *Escherichia coli* as described by the manufacturer (Amersham Biosciences) and cross-linked to glutathione-Sepharose 4B with dimethylpimelimidate. [^{35}S]-labeled MOZ protein was produced from pCI-MOZ by *in vitro* transcrip-

tion-translation with the TNT T7-coupled reticulocyte lysate system (Promega). A 5 μl aliquot of the reticulocyte lysate reaction containing [^{35}S]-labeled MOZ protein was incubated for 3 hr at 4°C with GST fusion proteins in buffer containing 50 mM Tris–HCl (pH 8.0), 150 mM KCl, 10% glycerol, 0.1% Tween 20, 1 mM phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol. After extensive washes, bound proteins were separated by SDS-polyacrylamide gel electrophoresis and detected by autoradiography.

RESULTS AND DISCUSSION

Molecular Cloning of cDNA Encoding rnMOZ

To generate PCR primers for identification of rnMOZ cDNA by RT-PCR, we compared the sequence of hsMOZ (GenBank accession no. U47742) with mouse expressed sequence tags (accession nos. AK028058, BC024786, and AK054354) and designed our primers on the basis of sequences identical between human and mouse. Seven fragments amplified from rat total RNA were sequenced and covered the entire ORF. The predicted primer-generated sequences, except for primers including the translation start and stop codons, were confirmed by sequencing of the amplified regions. The rnMOZ ORF (accession no. AB195309) included 5994 nucleotides and encoded 1998 amino acids (Fig. 1A).

Comparison of rnMOZ cDNA with Rat Genome Sequence

The genome sequence of the Brown Norway rat,

(A)

```
   1 MVKLANPLYTQWILEAIKKVKKQKQRPSEERICNAVSSSHGLDRKTVLEQLELSVKDGTILKVSNKGLNSYKDPDNPGRIALPKPRNHGKLDNKQSVDWNKLLKRAFEGLAESGGSTLKS
 121 IERFLKSQKDVSAACGGTAASGFHQQLRLAIKRAVGHGRLLKDGPLYRLNTKAANAEGKEGCESLSCLPPVSLLPHEKDKPVAEPIPICSFCLGTKEQNREKKPEDLISCADCGNSGHPS
 241 CLKFSPELTVRVRALRWQCIECKTCSSCRDQGKNADNMLFCDSCDRGFHMECCDPPLTRMPKGMWICQICRPRKKGRKLLQKKAAQIKRRYANPIGRPKNRLKKQSTVSKGPFSKVRTGP
 361 GRGRKRKITVSSQSASSSEEGYLERIDGLDFCRDSSAPLKFNKKTKGLIDGLTKFFTPSPDGRKARGEAVDYSELRIRKKGNRKSSTSHWPTDNQDGWESKQESEERLFGSQEIMTERDM
 481 ELFRDIQEQALQKVGVTGPPDPQVRCPSVIEFGKYEIHTWYSSPYPQEYSRLPKLYLCEFCLKYMKSRTILQQHMKKCGWFHPPANEIYRKNNISVFEVDGNVSTIYCQNLCLLAKLFLD
 601 HKTLYDVEPFLFYVLTQNDVKGCHLVGYFSKEKHCQQKYNVSCIMILPQYQRKGYGRFLIDFSYLLSKREGQAGSPEKPLSDLGRLSYMAYWKSVILECLYHQNDKQISIKKLSKLTGV
 721 CPQDITSTLHHLRMLDFRSDQFVIIRREKLIQDHMAKLQLNLRPVDVDPECLRWTPVIVSNSVVSEEEDEEADDGEKEEPQGQERELETRERVGKSVSRENKDQDSSSLIESEKKPEVKE
 841 LASSSRLSKQALVRDSLPANSQPPRRGRCGRKNRKTQERFGDKDSKMLVGETLSTSQEQYGECEEKSAASRERYTEVGEQPAAPQAQADGNPDIPKGRFSESADLWRGQLKKSPETLKCR
 961 LPEGNDRLPCCYTDGDRAVFRGFSESSEEEEEPESPRSNSPPVLTKPTLKRKKPILHRRRRVRKRKHHNSSVVTETISETTEVLDEPFEDSDSERPMPRLEPTFEIEEBEEEEDENELFP
1081 RGYFHCLSSQDILRCQASSKRTASKDEEEBEEESDDADDTPVLKPVSLLRKCDVNSASLEPDTSTPMKKKKGWPKGKSRKPIHWKKRPGRKPGFKLNQDIIAVSTQECIVEPIVPIKPGR
1201 KPRTQESEELVEVKEGLVEERKEEMHTEADEEAEEEEDAASSDIRAMSPLDSSNSPDADPKEPEAEEEEEKPLDDPRQSEEEPQELEEQEQEEEDEVTAEANQNEDHDADDEDDGHLDSL
1321 KTKEPEGQPAREDGTEEPGTQESFLDASIQDSRENAKDKDETEADSEEEQPSHEASVGSETMPGSEEDHEEDSNTKEELIELKEEEEIPHSELDLETVQAVQSLTQEESSEHEGAYQDCE
1441 ETLAACQTLQSYTHTDEDPQMSMVEDCHASEHNSPISSIPSHPSQSVRSVSSPSMPALESGYTQISPEQGSLSAPSMQNMETSPMMDVPSVSDHSQQVVDSGFSDLGSIESTTENYENPS
1561 SYDSTMGSSICGNNSSQSSCSYGGLSSSSSLTQNSCVVTQQMASMGNSCSMLQQNSVQPATNCNIKSPQTCVVERPPSNQQPPPPPPPPPPPPQQPQPQPQQQAAPQPPPPQPQQQPPPPP
1681 QQQPQPPPPPQQQPPLSQCSMNNSFTAAPMIMEIPESGGTGNISIYERIPGDFGAGSYSQPSATFSLAKLQQLTNTIMDPHAMPYSHSPAVTSYATSVSLSNTGLAQLAPSHPLAGTPQA
1801 QATMTPPPNLAPTTMNLTSPLLQCNMSATNIGIPHTQRLQGQMPVKGHISIRSKSAPLPSATAHQQQLYGRSPPAVAMQAGPRALAVQRGMNMGVNLMPTPAYNVNSMNMNTLNAMNSYR
1921 MTQPMMNSSYHSNPAYMNQTAQYPMQMQMGMMGSQAYTQQPMQPNPHGNMMYTGPSHHSYMNAAGVPKQSLNGPYMRR*1998
```

(B)

(C)

Fig. 1. Molecular Cloning of CDNA Encoding rnMOZ

(A) Deduced amino-acids sequence of rnMOZ. The numbers on the left refer to the corresponding to amino acid positions. (B) Schematic representation of the rnMOZ gene structure. The boxes indicate the relative sizes and positions of exons. (C) Comparison of the functional domains of orthologous MOZs. H15, histone H1- and H5-like motif; PHD, plant homeodomain zinc fingers; MYST, MYST acetyltransferase domain; ED, S, P, and M are Glu/Asp-, Ser-, Pro-, and Met-rich regions, respectively.

recently determined by the Rat Genome Sequencing Project Consortium, is available in the international sequence databases.[9] Comparison of rnMOZ with the genomic sequence revealed that the *rnMOZ* gene was located at 16q12.5 and comprised 16 exons spanning > 75 kb (Fig. 1B); all of the exon-intron boundaries were consistent with the GT/AG rule (data not shown). The sequence of rnMOZ cDNA was the same as the genomic sequence, except that the C, T, and C at nucleotides 3699, 4329, and 5058 of the cDNA were T, G, and T, respectively, in the genome. These differences may be due to differences in the stem lines. The predicted sequences of primers including the translation start and stop codons were also identical to the genome sequences, except that A at position 9 of cDNA was G in the genome sequence; however the predicted amino acids of rnMOZ were completely identical with those from the genomic sequence.

Comparison of rnMOZ with hsMOZ

Functional domains of hsMOZ have been identified.[10] Comparison of rnMOZ with hsMOZ revealed 89% identity over the whole sequence, and the percentage of identity at each domain is shown in Fig. 1C. All domains were highly conserved. In particular, the sequences of the MYST, PHD, and Met-rich domains, which are important for HAT activity and transcriptional regulation, were nearly identical between the orthologs.

Association of rnMOZ with bZIP-type Transcription Factors

Recruitment of HAT activity by DNA-binding transcription factors is a trigger for gene expression from chromatin. We observed the *in vitro* interac-

GST-fusion protein

Fig. 2. Association of rnMOZ with bZIP-Type Transcription Factors

[³⁵S]-MOZ was incubated with GST (lane 2) or GST-fused c-Jun (FL), c-Jun (AD), c-Jun (DBD), C/EBPα and CIEBPβ (lanes 3-7). MOZ protein retained on the GST-conjugated beads after extensive washes was analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography The amount of input (lane 1) was equivalent to 10% of the reaction in the assay.

tion between rnMOZ and various DNA-binding proteins by using the GST pull-down assay. c-Jun is a bZIP-type DNA-binding transcription factor,[6] and the GST pull-down assay revealed that [³⁵S]-labeled MOZ was retained on beads cross-linked with GST-c-Jun (FL) but not with GST alone. This finding suggests that rnMOZ is physically associated with c-Jun. The AD and the DBD of c-Jun have been determined.[11] We tried to identify the region in c-Jun that is required for interaction with rnMOZ and found that DBD, but not AD, of c-Jun was necessary for interaction with rnMOZ (Fig. 2). Further, we showed that both C/EBPα and C/EBPβ — other bZIP family members — also physically associate with rnMOZ (Fig. 2). These findings are the first evidence that MOZ interacts with DNA-binding transcription factors, and they suggest that MOZ may influence multiple cellular functions through bZIP-type transcription factors.

REFERENCES

1) Johnson, P. F. and McKnight, S. L. (1989) Eukaryotic transcriptional regulatory proteins. *Annu. Rev. Biochem.*, **58**, 799–839.

2) Sterner, D. E. and Berger, S. L. (2000) Acetylation of histones and transcription-related factors. *Microbiol. Mol. Biol. Rev.*, **64**, 435–459.

3) Thomson, S., Clayton, A. L. and Mahadevan, L. C. (2001) Independent dynamic regulation of histone phosphorylation and acetylation during immediate-early gene induction. *Mol. Cell*, **8**, 1231–1241.

4) Kitabayashi, I., Aikawa, Y., Nguyen, L. A., Yokoyama, A. and Ohki, M. (2001) Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. *EMBO J.*, **20**, 7184–7196.

5) Borrow, J. and Stanton, V. P., Jr., *et al.* (1996) The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. *Nat. Genet.*, **14**, 33–41.

6) Mann, D. A. and Smart, D. E. (2002) Transcriptional regulation of hepatic stellate cell activation. *Gut*, **50**, 891–896.

7) Sakai, M., Okuda, A., Hatayama, I., Sato, K., Nishi, S. and Muramatsu, M. (1989) Structure and expression of the rat c-jun messenger RNA: tissue distribution and increase during chemical hepatocarcinogenesis. *Cancer Res.*, **49**, 5633–5637.

8) Chen, P. L., Riley, D. J., Chen, Y. and Lee, W. H. (1996) Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. *Genes Dev.*, **10**, 2794–2804.

9) Gibbs, R. A., Weinstock, G. M., Metzker, M. L., Muzny, D. M. and Sodergren, E. J., *et al.* (2004) Genome sequence of the Brown Norway rat yields insights into mammalian evolution. *Nature* (London), **428**, 493–521.

10) Champagne, N., Pelletier, N. and Yang, X. J. (2001) The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase. *Oncogene*, **20**, 404–409.

11) Alani, R., Brown, P. and Binetruy, B., *et al.* (1991) The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells. *Mol. Cell. Biol.*, **11**, 6286–6295.

Instructions for Authors

The Journal of Health Science is published by the Pharmaceutical Society of Japan, and covers all aspects of health science. The Journal will publish high quality original research related to health, as effected by nutrients, endogenous factors, chemicals (including drugs), and microorganisms, employing the techniques of biochemistry, molecular biology, toxicology, and epidemiology. Reports on analytical methods and experimental techniques are also within the scope of the Journal.

The Journal will accept original and innovative submissions in English from both members and non-members of the Pharmaceutical Society of Japan, on the understanding that the work is unpublished and is not being considered for publication elsewhere.

Types of Manuscript

The Journal publishes Regular Articles, Rapid Communications, Research Letters, Reviews and Minireviews. With the exception of Reviews and Minireviews, manuscripts will be reviewed by two or more referees, whose opinions will form the basis of the final decision by the Editor.

(1) *Regular Articles*

New, significant, innovative and original findings are suitable as *Regular Articles*. Whilst the Journal does not publish Short Communications, relatively short *Regular Articles* are also acceptable if the work is of a high quality.

(2) *Rapid Communications*

These articles should be 4 or less printed journal pages. Manuscripts are reviewed rapidly. Authors are informed of the editor's decision by FAX or E-mail within 2 weeks after reception of the manuscript. The editor's decision is either acceptance or rejection for publication, and no revision process will take place. Responsibility for the scientific contents of a manuscript remains with the author. In the case of rejection, a short explanation only will be provided. When submitting *Rapid Communications*, please include a floppy disk containing the text and any figures, tables etc.

(3) *Research Letters*

Research Letters should occupy 3 printed journal pages or less. Manuscripts containing interesting findings without adequate discussion, research results of narrow scope or of a predominantly negative nature may nevertheless be suitable for publication as a *Research Letter* if they are considered sufficiently important. Subjects of relevance to health science, for example DNA sequences of unknown genes and transcriptional regulation regions etc, are also suitable as *Research Letters*. Manuscripts containing valuable data obtained in field work are also acceptable. When it is necessary to present a relatively large amount of data

in field work, the paper may extend to more than 3 printed pages.

(4) *Reviews and Minireviews*

Reviews and Minireviews are submitted by invitation from the Editorial Board, and encompass recent important scientific discoveries. *Minireviews* mainly involve a description of recent research results from the author's laboratory. *Reviews* are more broad based. Whilst *Reviews* do not have a page limit, *Minireviews* should be 3 pages or less of printed Journal space.

Submission of Manuscripts

Manuscripts (in triplicate) should be submitted to :

(From Japan)
Journal of Health Science Editorial Office
The Pharmaceutical Society of Japan
2-12-15, Shibuya, Shibuya-ku, Tokyo 150-0002,
Japan

(From the rest of the world)
Dr. Y. James Kang
Associate Editor, Journal of Health Science
Department of Medicine,
University of Louisville School of Medicine
511 S. Floyd St., MDR 530, Louisville, Kentucky
40202, U.S.A.

Manuscript Preparation

(1) *Manuscript Form* : All manuscripts should be typewritten in English on A4 paper, double space (24 lines per page, approx. 70 strokes per line). Since after printing, one page contains about 4300 characters, please take care when preparing the paper to not exceed the allowed length for the specific type of manuscript. The top (title) page should be numbered 1 at the bottom center. All subsequent pages should be numbered consecutively.

(2) *Title Page* : The title page (page 1) should start with the title, name(s) of the author(s) and affiliation and mailing address. An asterisk (*) should be added to the right of the corresponding author's name. Below the authors address(es) should be included the type of manuscript (Regular Article, Research Letter etc.) and the corresponding author's name, address, telephone number, fax number, and E-mail address.

(3) *Summary and Keywords* : Page 2 should contain a summary of less than 250 words and 3 to 6 descriptive key words, listed in order of importance. The first 3 key words must be independent, as they will be used in a key-word combination in the index.

(4) *Main Text* : The main text should start from page 3 and be divided into the follow sections: Introduction, Materials and Methods, Results, Discussion, Acknowledgments, and References. It is also acceptable to merge the Results

with the Discussion in the form: Results and Discussion.

(5) *Abbreviations and Units* : Abbreviation must be spelled out in full at their initial appearance, followed by the abbreviation in parentheses. Thereafter, the abbreviation may be employed. The following units should be used: length (m, cm, mm, nm, μm, Å), mass (kg, g, mg, μg, ng, pg, mol, mmol), volume (l, ml, μl), time (sec, min, hr), temperature (°C), radiation (Bq, Ci, Sv, Gy), concentration (M, mM, mol/l, mmol/l, mg/ml, μg/ml, %, %(v/v), ppm, ppb).

(6) *Figures* : In principle, figures prepared by the author will be used in the printed version of the journal. All figures should be numbered consecutively with Arabic numbers, and figure titles and legends are to be typed consecutively on a separate sheet. All figures should be prepared on A4 paper, and the authors name should be added at the top of each page.

(7) *Tables* : Tables should be typed on A4 paper and numbered consecutively with Arabic numbers. Any explanations of data or methods in the table should be directly below the table.

(8) *References* : References should be placed and numbered in the order of appearance in the text. Each number is to be positioned after the last relevant word with a right-half parenthesis mark, and all references should be collected together at the end of the text. Abbreviations for Journals should conform to Chemical Abstracts nomenclature.

Examples of References are as follow :

1) Kubo, U., Hwang, G. H. and Suzuki, H. (2000) Cloning and functional characterization of copper transporter. *J. Health Sci.*, **46**, 135–140.

2) Albert, B. and Hardin, T. D. (1998) *Metal Toxicology in Mammals*, Madison Press, New York.

3) Meister, B., Revel, T. M. and Caprio, M. N. (1999) Molecular mechanism of cell death. In *Handbook of Health Science* (Clarke, A. and Young, T. A., Eds.), Carrie Press, Tokyo, pp.135–137.

(9) *Notes* : Notes should be given in parentheses at the appropriate place in the text. Footnotes are not permitted.

Ethics

In scientific investigations involving human subjects, experiments should be performed in accordance with the ethical standards formulated in the Helsinki Declaration of 1964 (revised in 2000, cf. http://ohsr.od.nih.gov/). Similarly, animal experiments should follow the ethical standards formulated in the guidelines issued by the Science and International Affairs Bureau of the Japanese Ministry of Education, Science, Sports and Culture, No.141, 1987: "Animal Experiments in Universities etc."

Page Charges

Authors are required to pay charges, as outlined below :

(1) Page Charge : 4000 yen per printed page (not including tax). Charges may be changed without prior notice.

(2) Reprint Charges are as undermentioned table.

(3) Color Figures : Actual cost.

(4) The payment of page charge is required, but is not a condition for publication, since the decision for publication is made on the basis of scientific significance only. The publication charge may be waived upon request from authors who do not have funds. No free reprints of the article are provided.

Miscellaneous

(1) Any author who is not fully fluent in idiomatic English is urged to gain assistance with manuscript preparation from an appropriate person who can check and improve the English of their paper.

(2) Rejected manuscripts will not be returned to the author.

(3) Revised manuscripts must be returned with 2 months, otherwise they will be treated as new submissions.

(4) Except for Rapid Communications, a floppy disk containing text and figure files must be sent with the revised manuscript.

(5) The author is given an opportunity to proof the galley of an accepted manuscript. Major changes at this time are not permitted.

(6) Copyrights : The copyrights of all manuscripts published in Journal of Health Science belong to the Pharmaceutical Society of Japan. The author must submit a Copyright Transfer form to the Pharmaceutical Society of Japan.

(http://jhs.pharm.or.jp)

Reprint Charges

Number of Pages / Number of Reprints	1~2	3~4	5~6	7~8	9~10	Greater than 11
50	¥ 8000	¥ 9000	¥ 10000	¥ 11000	¥ 12000	¥ 13000
100	¥ 14400	¥ 16200	¥ 18000	¥ 19800	¥ 21600	¥ 23400
150	¥ 19200	¥ 21600	¥ 24000	¥ 26400	¥ 28800	¥ 31200
200	¥ 22400	¥ 25200	¥ 28000	¥ 30800	¥ 33600	¥ 36400
More than 250	¥ 110 each	¥ 120 each	¥ 130 each	¥ 150 each	¥ 160 each	¥ 180 each

· Postage included ; Tax extra.   · Color printing carries on extra surcharge of ¥80 per page.

· Reprints only available in multiples of 50.

Trialkyltin Compounds Bind Retinoid X Receptor to Alter Human Placental Endocrine Functions

Tsuyoshi Nakanishi, Jun-ichi Nishikawa, Youhei Hiromori, Hideaki Yokoyama, Mihoko Koyanagi, Shinri Takasuga, Jun-ichi Ishizaki, Mai Watanabe, Shun-ichi Isa, Naoki Utoguchi, Norio Itoh, Yutaka Kohno, Tsutomu Nishihara, and Keiichi Tanaka

Department of Toxicology (T.N., Y.H., H.Y., M.K., S.T., J.I., M.W., S.I., N.I., K.T.) and Laboratory of Environmental Biochemistry (J.N., T.N.), Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871; Laboratory of Pharmaceutics (N.U.), School of Pharmaceutical Sciences, Teikyo University, Sagamiko, Kanagawa 199-0195; and Development Division (Y.K.), Fujisawa Pharmaceutical Co., Ltd., Osaka 532-8514, Japan

Retinoid X receptor (RXR) is a nuclear receptor that plays important and multiple roles in mammalian development and homeostasis. We previously reported that, in human choriocarcinoma cells, tributyltin chloride and triphenyltin hydroxide, which are typical environmental contaminants and cause masculinization in female mollusks, are potent stimulators of human chorionic gonadotropin production and aromatase activity, which play key endocrine functions in maintaining pregnancy and fetal development. However, the molecular mechanism through which these compounds stimulate these endocrine functions remains unclear. Our current study shows that trialkyltin compounds, including tributyltin chloride and triphenyltin hydroxide, function as RXR agonists. Trialkyltins directly bind to the ligand-binding domain of RXR with high affinity and function as transcriptional activators. Unlike the natural RXR ligand, 9-*cis*-retinoic acid, the activity of trialkyltins is RXR specific and does not activate the retinoic acid receptor pathway. In addition, trialkyltins activate RXR to stimulate the expression of a luciferase reporter gene containing the human placental promoter I.1 sequence of aromatase, suggesting that trialkyltins stimulate human placental endocrine functions through RXR-dependent signaling pathways. Therefore, our results suggest that activation of RXR may be a novel mechanism by which trialkyltins alter human endocrine functions. (*Molecular Endocrinology* 19: 2502–2516, 2005)

T HE RETINOID X receptors RXRα, RXRβ, and RXRγ, which are type II nuclear receptors, are thought to be key factors in several nuclear receptor signaling pathways. These molecules specifically bind 9-*cis*-retinoic acid (9cRA) and thus may be directly involved in the transduction of retinoid signals. In

transfected cultured cells, as well as established cell lines, RXRs can act either as homodimers or heterodimeric partners of several other nuclear receptors, including retinoic acid receptors (RARα, -β, and -γ), thyroid hormone receptors (TRα and -β), vitamin D receptor (VDR), peroxisome proliferator-activated receptors (PPARα, -γ, and -δ), and a number of orphan receptors (1–3). Therefore, RXRs may be central to the modulation of several hormonal signals.

The placenta is a transient, but vital, organ for maintaining pregnancy in mammals. Its functions range from nutrient and gaseous exchange to hormone and growth factor production. Several observations suggest that RXRs play indispensable roles in placental development and physiology. In mice, RXRα transcripts are strongly expressed in the ectoplacental cone and, at later stages, in giant trophoblastic cells and the labyrinthine zone of the chorioallantoic placenta (4). RXR knock-out experiments in mice have revealed that RXRα and RXRβ are involved in the formation of the chorioallantoic placenta (5, 6). In particular, the inactivation of RXRα ligand-dependent transcriptional activation function 2, but not ligand-independent transcriptional activation function 1, prevents the formation of labyrinthine trophoblasts and leads to fetal death during the late fetal period or

shortly after birth (7). These placental abnormalities are similar to those found in the placentas of vitamin A-deficient rats (8). These observations suggest that the ligand-dependent transcriptional activation of RXRα is physiologically required for placentation in rodents.

RXRα mRNA and protein have been detected in human cytotrophoblasts and choriocarcinoma cells (9–11). Treatment of these cells with 9cRA and synthetic RXR-specific ligands increases the level of mRNA expression of steroidogenic enzymes, such as aromatase and human (h) chorionic gonadotropin (CG) (9, 10, 12–15). Estrogens and hCG are the principal hormones produced by the placenta during human pregnancy. These hormones are essential for several important events in the establishment and maintenance of pregnancy. Biosynthesis of estrogens requires the catalytic activity of an aromatase enzyme complex, which converts androgenic to estrogenic steroids (16). The human placenta exhibits a high level of aromatase activity and therefore regulates the balance of estrogens *in utero* (17). Altering aromatase function *in utero* can cause permanent effects in human embryos; the lack of placental aromatase causes female pseudohermaphroditism, as is seen in patients with aromatase deficiency (16, 18).

hCG is a luteotropic factor and the primary marker of pregnancy in humans. Stimulation by hCG governs not only progesterone production in the corpus luteum during the first trimester (19) but also testosterone production within the fetal testes (20). Given the pivotal functional roles of aromatase and hCG in sexual development and reproduction, the extant retinoid signals of RXR-mediated transcription in the placenta may greatly alter fetal development because of their disruption of these endocrine functions.

Organotin compounds have been used widely as biocides, agricultural fungicides, wood preservatives, disinfecting agents in circulating industrial cooling waters, and antifouling paints for marine vessels (21, 22). There are many reports of the biological effects of organotin compounds, which vary in their toxic effects to eukaryotes. One of the most notable toxicities in sexual development and reproduction is that of tributyltin (TBT)- and triphenyltin (TPT)-mediated endocrine disruption in some species of gastropods (23, 24). This phenomenon is known as "imposex," the superimposition of male genitalia on female. Therefore, these trialkyltin compounds are suspected to cause endocrine-disrupting effects in mammals, including humans. Human exposure to organotin compounds may result from the consumption of organotin-contaminated meat and fish products, occupational exposure during the manufacture and formulation of organotin compounds, or the application and removal of organotin-containing paints (25, 26). The possible exposure of humans to organotins has therefore aroused great concern about potential toxicities.

Previously, we reported that both tributyltin chloride (TBTCl) and triphenyltin hydroxide (TPTOH) enhance

hCG secretion and aromatase activity in human choriocarcinoma cells. In addition, these compounds cause dose-related increases in the steady-state mRNA levels of both hCGβ and aromatase in human choriocarcinoma Jar cells after their exposure to nontoxic concentrations (27). These results suggest that these trialkyltin compounds are potent stimulators of human placental hCG production and aromatase activity *in vitro* and act as endocrine disruptors, the effects of which might alter local hCG and estrogen concentrations in pregnant women. However, the molecular mechanism underlying trialkyltin-induced alterations of human placental endocrine functions remains unclear. To extend our knowledge of the correlation between the structure of organotin compounds and their endocrine-disrupting effects, we assessed the effects of 17 tin compounds on hCG secretion, aromatase activity, and the mRNA levels of hCG and aromatase in Jar cells. We found that the effects of organotin compounds are related to both the number and length of their alkyl chains, suggesting that organotin compounds might interact with a target molecule in a fashion similar to that by which environmental estrogenic chemicals interact with estrogen receptors (28–34). Further, the promoter sequences of both human placental hCGβ and aromatase have several common half-site sequences (T/AGGTCA), of which nuclear receptor response elements typically are composed (13, 14). In addition, expression of both human placental hCG and aromatase is induced by specific RXR ligands (9, 10, 13, 14). In light of all of these results, we hypothesize that organotin compounds interact with RXRs to alter placental endocrine functions. Here we demonstrate that trialkyltin compounds bind to RXRs with high affinity and stimulate transcription through these receptors to alter endocrine functions in human choriocarcinoma cells.

RESULTS

Effects of Organotin Compounds on hCG Production and Aromatase Activity in Human Choriocarcinoma Cells

Previously, we reported that both TBTCl and TPTOH enhance hCG secretion and aromatase activity in human choriocarcinoma cells (27). To extend our knowledge of the correlation between the structures of organotin compounds and their endocrine-disrupting effects, we assessed the effects of 17 tin compounds (Fig. 1) on hCG secretion from, and aromatase activity in, Jar choriocarcinoma cells after their exposure to nontoxic concentrations of these compounds, which were determined from the results of [³H]thymidine uptake assays (data not shown). The most active compounds were TBT or TPT derivatives (Fig. 2, Group III). Exposure to ≥ 10 nM of each of these trialkyltin compounds caused statistically significant increases in hCG production by Jar cells. Aromatase activity also

Fig. 1. Structures of the Tin Compounds Used in This Study
The abbreviation for, and purity of, each compound used are indicated in *parentheses.*

increased significantly as the concentrations of the TBT derivatives increased beyond 10 nM or those of the TPT derivatives increased in excess of 30 nM. Among the other trialkyltin compounds (Group I), tripropyltin chloride (TPrTCl) and tricyclohexyltin hydroxide (TChTOH) were active. Like the TBT and TPT compounds, TPrTCl stimulated both hCG production and aromatase activity, whereas TChTOH stimulated hCG production but not aromatase activity. Among the butyltin and phenyltin derivatives (Group II), neither of the mono-alkyltin compounds altered hCG production or aromatase activity. Dibutyltin dichloride (DBTCl₂) stimulated aromatase activity at 30 nM but failed to induce hCG production at any of the concentrations tested. In contrast, diphenyltin dichloride (DPTCl₂) stimulated hCG production at 30 nM but not aromatase activity at any tested concentration.

There were no significant differences in hCG production and aromatase activity among the TBT and TPT derivatives (Group III), suggesting that the ligand on the trialkyltin (as long as it is not an alkyl group) is relatively unimportant to the stimulation of these endocrine functions. However, the presence of a fourth alkyl group on the tin atom decreased the stimulus potency of the alkyltin compounds on hCG production and aromatase activity, because both tetrabutyltin (TeBT) and tributylvinyltin (TBVT) failed to. stimulate these placental functions at doses less than 100 nM (Fig. 2, Group III). These results suggest that the potency of the effects induced by alkyltin compounds is related to both the number and length of the alkyl groups.

In addition, we investigated the tin compound-induced mRNA expression of hCGβ and aromatase at either the concentration that elicited the greatest response in each endocrine function or the maximal nontoxic concentration. The changes in hCGβ and aromatase mRNA expression were almost parallel to those in hCG secretion and aromatase activity (Fig. 3). These results indicate that the observed alkyltin-induced alterations in these placental functions are both caused by regulation at the mRNA level. Such overt correlation between the mRNA expression induced by alkyltin compounds and their structure led us to hypothesize that alkyltin compounds may interact with a nuclear receptor to alter placental endocrine functions; a similar mechanism has been demonstrated for environmental estrogenic chemicals that interact with estrogen receptors (28–34).

Interaction of Alkyltin Compounds with the Hormone-Binding Domain of RXRs

In human placental cells, both hCG production and aromatase activity are controlled by cAMP-dependent intracellular signal pathways. However, in our previous study, neither TBTCl nor TPTOH exerted any effect on cAMP production (27). After a literature search to identify a signaling pathway common to the mRNA expression of both hCG and aromatase, we arrived at the hypothesis that alkyltin compounds act as ligands of RXRs to activate the transcription of hCG and aromatase, because these placental factors are both induced by specific ligands of RXRs (9, 10, 13, 14). In

Fig. 2. Effects of Tin Compounds on hCG Secretion (A, C, and E) and Aromatase Activity (B, D, and F) in Jar Cells

Cells were treated with various nontoxic concentrations of tin compounds for 48 h. A nontoxic concentration of a tin compound was defined as a concentration at which the uptake of [^{3}H]thymidine was $\geq$ 80% that for the vehicle alone (data not shown). Results are expressed as mean $\pm$ 1 SD of triplicate cultures. Group I (A and B): comparison of different lengths of alkyl chains in trialkyltin compounds. Group II (C and D): comparison of different numbers of alkyl chains in butyltin and phenyltin compounds. Group III (E and F): comparison of different fourth function groups on the tin of TBT and TPT. The hCG production and aromatase activity in vehicle-only cells, calculated from all experiments, were 290.0 $\pm$ 85.3 mIU/well·24 h and 4.08 $\pm$ 0.91 pmol/well·4 h, respectively.

fact, we were able to confirm that a natural RXR ligand, 9cRA, and a synthetic RXR-specific ligand, LG100268, induced mRNA expression of both hCGβ and aromatase in Jar cells (Fig. 4).

Accordingly, we examined the dose-response effectiveness of TBTCl and TPTOH in stimulating RXR activity by using human choriocarcinoma JEG-3 cells cotransfected with a human RXRα expression plasmid and a luciferase (LUC) reporter plasmid containing an RXR response element (RXRE). RXR homodimers bind to direct repeat (DR)1 motifs (1–3). We constructed and used pTALDR1, which contains two DR1 sequences, as a reporter plasmid. Treatment with 1–100 nM 9cRA resulted in a 3- to 10-fold increase in LUC activity, whereas similar treatment with LG100268 led to a 3.3- to 4.5-fold increase (Fig. 5A). In addition, 100 nM 9cRA slightly stimulated the expression of LUC in JEG-3 cells transfected with a control plasmid, because JEG-3 cells express endogenous RXRα (10).

Treatment of RXRα-transfected JEG-3 cells with 1–100 nM TBTCl stimulated LUC expression 1.5- to 9-fold, and exposing the cells to the same concentrations of TPTOH induced LUC expression 1.8- to 19-fold; these results suggest that low doses of these trialkyltin compounds activate RXR.

To identify the region of RXR involved in activation by alkyltin compounds, we used a chimeric receptor consisting of the DNA-binding domain of the yeast transcription factor GAL4 and the ligand-binding domain (LBD) of RXRα (GAL-RXR). Consistent with the results in Fig. 5A, the activity of the LUC reporter construct in JEG-3 cells cotransfected with the GAL-RXR chimeric receptor and the UAS-LUC reporter increased in a dose-dependent manner after incubation with not only 9cRA but also either TBTCl or TPTOH (Fig. 6). We then investigated the effect of the other tin compounds on activation of GAL-RXR chimeric receptors after exposure of the cells to nontoxic concentra-

Fig. 3. Effects of Tin Compounds on the mRNA Expression of hCG β (A, C, and E) and Aromatase (B, D, and F) in Jar Cells

Total RNA isolated from Jar cells was treated with tin compounds for 24 h (open bars) and 48 h (solid bars). The concentrations of each compound were: 10 μM of TOTH, SnCl$_4$, MBTCl$_3$, and TBVT; 3 μM of MPTCl$_3$ and TeBT; 1 μM of 9cRA and TMTCl; 300 nM of DPTCl$_2$; 100 nM of TETBr, TBTCl, TPTOH, TPTCl, TBTBr, and TBTH; and 30 nM of TPrTCl, TChTOH, and DBTCl$_2$. The relative hCGβ and aromatase mRNA levels for each condition were determined by quantitative RT-PCR three times for each of the three independent cultures (see Materials and Methods). Results are expressed as mean ± 1 SD of three independent cultures. Groups I (A and B), II (C and D), and III (E and F) correspond to the groups described in the legend for Fig. 2. *, P < 0.05; **, P < 0.01; and ***, P < 0.005 vs. vehicle.

Fig. 4. Effects of Various Nuclear Receptor Agonists on the mRNA Expression of hCG β (A) and Aromatase (B) in Jar Cells

Total RNA isolated from Jar cells was treated with tin compounds for indicated time periods. The concentrations of each compound were: 10 μM of CDCA; 100 nM of 9cRA, atRA, rosiglitazone, or 15dPGJ$_2$; and 100 nM of LG100268 or AM580. The relative hCGβ and aromatase mRNA levels for each condition were determined by quantitative RT-PCR three times for each of the three independent cultures (see Materials and Methods). Results are expressed as mean ± 1 SD of three independent cultures. *, P < 0.05; **, P < 0.01; and ***, P < 0.005 vs. vehicles.

tions. TPrTCl, TeBT, and TBVT, as well as the TBT and TPT derivatives, activated transcription through GAL-RXR. TChTOH also activated transcription though GAL-RXR markedly, but the level of activation was only slight compared with that induced by the TBT and TPT derivatives. The level of GAL-RXR activation induced by these tin compounds was almost parallel to the increase in mRNA expression of hCGβ or aromatase in JEG-3 cells treated with these compounds.

RXR serves as a common heterodimerization partner for several receptors (1–3). In addition to RXR

homodimer, RXR-specific ligands can activate two types of complex. One type is the permissive heterodimers, such as PPAR-RXR (35–39) and farnesoid X-activated receptor (FXR)-RXR (40), which can be fully activated by a ligand of either RXR or its partner receptor and are activated synergistically in the presence of both ligands; the other is the conditionally permissive heterodimer RXR-RAR, which can be conditionally activated by RXR ligands only in the presence of an RAR agonist (38, 41). To identify the complexes involved in alkyltin-induced mRNA expression of both placental factors, we assessed the effects of the ligands of various RXR partners. The PPAR ligand 15-deoxy-$\Delta^{12,14}$-prostaglandin J$_2$ (15dPGJ$_2$) and the PPARγ-specific ligand rosiglitazone induced mRNA expression of hCGβ, but not aromatase, in Jar cells. Chenodeoxycholic acid (CDCA), an FXR agonist, failed to increase the mRNA expression of either placental factor. However, a natural RAR ligand, all-trans-retinoic acid (atRA), and a synthetic RARα-specific ligand, AM580, induced expression of the mRNA of both hCGβ and aromatase in human placental cells, as previously described (15). Furthermore, the natural RXR ligand 9cRA also can function as an RAR agonist to transactivate RXR-RAR heterodimer (1–3, 42). Accordingly, we examined whether typical trialkyltin compounds, which function as RXR agonists, can activate RXR-RAR transcription, as does 9cRA, by using LUC reporter plasmids containing an RAR response element (DR2 or DR5). Cells simultaneously transfected with human RXRα and RARβ expression vectors dramatically respond to atRA and 9cRA (Fig. 5B). Although TBTCl and TPTOH also stimulated the expression of LUC, the effectiveness of these organotin compounds was comparable to

Fig. 5. Ability of TBTCl and TPTOH to Activate RXR and RAR

A, JEG-3 cells were cotransfected with 10 ng of either pSVhRXRα or pSVSPORT1 in addition to 0.1 μg pTALDR1 (see *Materials and Methods*) and then treated with various concentrations of 9cRA, LG100268, TBTCl, or TPTOH. B, JEG-3 cells were cotransfected with 10 ng each of pS-VhRXRα and pSV40hRARβ in addition to 50 ng pTALDR2 or pTALDR5 and then treated with 100 nM of atRA, 9cRA, LG100268, TBTCl, or TPTOH. pRL-TK (2 ng) was cotrans-fected as the control for normalization (see *Materials and Methods*). The results are expressed as average fold activa-tion ± 1 sD after normalization to *Renilla* LUC activity. *, P < 0.05; **, P < 0.01; and ***, P < 0.005.

Fig. 6. Ability of Tin Compounds to Activate GAL-RXR

JEG-3 cells were cotransfected with 10 ng p4xUAS-tk-luc, 5 ng pBK-CMV-GAL4-hRXRα, and then treated with 9cRA or each of the tin compounds. The doses of each compound were: 0, 1, 10, or 100 nM of 9cRA, TETBr, TBTCl, TPTOH, TPTCl, TBTH, or TBTBr; 0, 0.1, 1, or 10 μM of TOTH, SnCl₄, MBTCl₃, or TBVT; 0, 1, 10, or 30 nM of TPrTCl, TChTOH, or DBTCl₂; 0, 0.1, 1, or 3 μM of MPTCl₃ or TeBT; 0, 10, 100, or 300 nM of DPTCl₂; and 0, 10, 100, or 1000 nM of TMTCl. pRL-TK (2 ng) was cotransfected as the control for normal-ization (see *Materials and Methods*). The results are ex-pressed as average fold activation ± 1 sD after normalization to *Renilla* LUC activity. Groups I, II, and III correspond to the groups described in Fig. 2. *, P < 0.05; **, P < 0.01; and ***, P < 0.005.

that of LG100268, which does not transactivate RXR-RAR heterodimer (Fig. 5B). In addition, we ex-amined the effect of TBTCl and TPTOH on activation of RARα, -β, and -γ by using chimeric receptors in which the GAL4 DNA binding domain was fused to the LBD of RARs (GAL-RARs) instead of RXRα. Nei-ther alkyltin compound activated transcription through GAL-RARs (data not shown). These results suggest that the alkyltin compounds, which activate transcription of the reporter construct through GAL-RXR, interact with the LBD of RXR and transactivate RXR homodimer, but not RXR-RAR heterodimer, un-like 9cRA. Taken together, these results suggest that RXR homodimer may be involved in the alkyltin-induced mRNA expression of both placental factors, provided that the hCGβ induced also involves PPAR-RXR heterodimers.

Binding of Tin Compounds to RXR

To characterize the binding affinities of these tin com-pounds to RXR directly, we performed analyses of the saturation binding of [¹⁴C]TPTOH and [³H]9cRA to chi-meric receptors, which consisted of glutathione S-transferase (GST) fused to the LBD of human RXRs (GST-RXRs). The binding of 9cRA to GST-RXRs was specific and saturative (Fig. 7). Scatchard analyses of the binding of [³H]9cRA to GST-RXRα, -β, and -γ yielded dissociation constant (K_d) values of 11.7, 15.5, and 8.66 nM, respectively. These K_d values were sim-ilar to those previously reported (3, 42), suggesting that this system is useful for determining the binding affinity of alkyltin compounds to RXRs. Scatchard analyses of the binding of [¹⁴C]TPTOH to RXRα, -β, and -γ yielded K_d values of 55.5, 241, and 95.3 nM, respectively (Fig. 7). Although the K_d values of TPTOH for RXRs were approximately 5- to 15-fold higher than those for 9cRA, our results indicate that TPTOH binds to the RXRs with high affinity in a saturable and spe-cific manner.

Fig. 7. Saturation Kinetics for the Binding of [^{3}H]9cRA and [^{14}C]TPTOH to hRXRα, -β, and -γ

Specific binding (*solid square*) is defined as total binding (*solid circle*) minus nonspecific binding (*solid triangle*). Scatchard analysis was performed on specific binding data (triplicates at each point) to yield the indicated dissociation constants (K_d value) for each receptor.

To further test which of the other tin compounds might bind to RXR as a ligand, we performed competitive ligand-binding assays. We measured the ability of [^{3}H]9cRA or [^{14}C]TPTOH to compete with the tin compounds for binding to GST-RXRα. The TBT and TPT derivatives all competed with [^{3}H]9cRA for binding to GST-RXRα in a concentration-dependent manner (Fig. 8). Consistent with the K_d value of TPTOH for RXRα, the IC$_{50}$ value of TPTOH for binding [^{3}H]9cRA was approximately 5-fold higher than that of unlabeled 9cRA. The IC$_{50}$ values of the other TBT and TPT derivatives for binding [^{3}H]9cRA were almost the same as that of TPTOH, demonstrating that these trialkyltin compounds bind directly to RXR. In contrast to the results of competitive assay for [^{3}H]9cRA, 9cRA failed to completely out compete [^{14}C]TPTOH for binding to GST-RXRα, whereas the TBT and TPT derivatives successfully competed for binding (Fig. 8B). The IC$_{50}$ value of 9cRA for binding [^{14}C]TPTOH was more than 10-fold higher than those of TBTs and TPTs (Table 1). Further, TPrTCl bound to GST-RXRα as well as did the TBT and TPT derivatives, because its IC$_{50}$ values for binding [^{3}H]9cRA and [^{14}C]TPTOH were almost the same as those of the TBT and TPT derivatives (Fig. 8 and Table 1). However, TChTOH, TeBT, and TBVT failed to compete with [^{3}H]9cRA for binding to GST-RXRα, despite their ability to activate RXRα. Although TChTOH out competed [^{14}C]TPTOH for binding to GST-RXRα, TeBT only slightly out competed [^{14}C]TPTOH, and TBVT failed to compete with [^{14}C]TPTOH for binding to GST-RXRα (Table 1). By contrast, triethyltin bromide (TETBr), which was unable to activate tran-

scription through an RXR, bound weakly to GST-RXRα. The IC$_{50}$ values of TETBr for binding [^{3}H]9cRA and [^{14}C]TPTOH were approximately 25- to 50-fold higher than those of the TBT and TPT derivatives (Table 1). The remaining tin compounds (trimethyltin chloride, TMTCl; trioctyltin hydride, TOTH; butyltin trichloride, MBTCl$_3$; phenyltin trichloride, MPTCl$_3$; DBTCl$_2$; DPTCl$_2$; and SnCl$_4$) did not compete successfully with either [^{3}H]9cRA or [^{14}C]TPTOH for binding to GST-RXRα, suggesting that they were unable to bind to RXRs.

Trialkyltin Compounds Stimulate the Expression of an LUC Construct Containing the Human Placental I.1 Sequence of Aromatase via Activation of RXRα

To determine whether trialkyltin compounds, which bind to and activate RXRs, induce aromatase expression in the human placenta via ligand-dependent activation of RXRs, we assessed the dose-response effectiveness of TBTCl and TPTOH by using JEG-3 cells cotransfected with a human RXRα expression plasmid and a LUC reporter plasmid containing the promoter sequence (−2295 to +107 bp) of exon I.1, which is the major promoter of human placental aromatase (Fig. 9A; and Refs. 16, 43, and 44). As expected, LG100268 stimulated the expression of LUC by 2.4- to 3.5-fold. These results suggest that the aromatase promoter is regulated by ligand-bound RXR (13). In addition, TBTCl and TPTOH stimulated the expression of LUC in

Fig. 8. Competition by 9cRA and Alkyltin Compounds with [^{3}H]9cRA (A) and [^{14}C]TPTOH (B) for Binding to the LBD of hRXRα

The LBD of hRXRα protein was incubated with increasing concentrations of unlabeled 9cRA or alkyltin compounds as competitors in the presence of [^{3}H]9cRA or [^{14}C]TPTOH as ligand. Results are expressed as percent specific binding. Each experiment was performed at least twice, and representative curves are shown.

Table 1. IC$_{50}$ of Tin Compounds for Competition of [^{3}H]9cRA and [^{14}C]TPTOH·Binding to hRXRα, and EC$_{50}$ of Tin Compounds for GAL-RXR Reporter Assay

Compound	IC$_{50}$ of Competition Assay (µM)		EC$_{50}$ of GAL-RXR Activity (nM)
	[^{3}H]9cRA	[^{14}C]TPTOH	
9cRA	0.107	26.9	10.2
TBTCl	0.468	2.26	14.4
TBTH	0.475	2.37	12.3
TBTBr	0.265	2.56	10.4
TPTOH	0.527	1.82	13.9
TPTCl	0.792	1.63	13.4
TPrTCl	0.921	2.11	9.0
TChTOH	>10	2.68	17.3
TeBT	>10	23.7	559
TBVT	>10	>200	2960
TETBr	6.76	80.1	N.D.[a]
TMTCl	>10	>200	N.D.
TOTH	>10	>200	N.D.
SnCl$_4$	>10	>200	N.D.
MBTCl$_3$	>10	>200	N.D.
DBTCl$_2$	>10	>200	N.D.
MPTCl$_3$	>10	>200	N.D.
DPTCl$_2$	>10	>200	N.D.

[a] Not detectable.

a dose-dependent manner to levels approaching those induced by 9cRA and LG100268.

Because RAR agonists induced mRNA expression of aromatase (Fig. 4B), we examined the effectiveness of cotransfection with a human RARβ expression plasmid in stimulating the LUC activity by these alkyltin compounds to identify whether RAR is involved in alkyltin-induced aromatase expression (Fig. 9B). In the presence of the natural RAR ligands, atRA or 9cRA, RAR statistically significantly increased the expression of LUC ($P < 0.05$ or $P < 0.01$), whereas RAR had no effect on the LUC activity induced by LG100268, TBTCl, or TPTOH (Fig. 9B). These results suggest that the expression of human placental aromatase induced by these alkyltin compounds is involved in a ligand-dependent signaling pathway of RXRs but not in transactivation of RXR-RAR.

DISCUSSION

Although our previous study of human placental cells showed that TBTCl and TPTOH enhance hCG secretion and aromatase activity with an accompanying increase in the mRNA expression of each factor (27),

the underlying molecular mechanism had remained unclear. In our previous study, we examined the effect of TBTCl and TPTOH on cAMP concentrations in human choriocarcinoma cells, because hCG production and aromatase activity in the human placenta are both well known to be controlled by cAMP-dependent intracellular signal pathways (16, 17, 45, 46). However, neither of these trialkyltin compounds altered cAMP production (27). We then speculated that activation of RXRs is a common signaling pathway of alkyltin-stimulated hCG production and aromatase activity, because both of these events are induced by specific ligands of RXRs (Fig. 4 and Refs. 9, 10, 13, and 14). In our present study, we provide evidence that trialkyltin compounds stimulate the transcription of RXRs because of a high-affinity interaction with the LBD of the receptor. In addition, trialkyltin compounds stimulate the expression of an LUC reporter construct containing the human placental promoter I.1 sequence of aromatase via a ligand-dependent signaling pathway of RXR.

In humans, the tissue-specific expression of aromatase is strictly regulated. Human aromatase is a single-copy gene composed of 10 exons: exons II through X encode the aromatase protein as well as the 3′-untranslated region of mRNA common to all estrogen-producing tissues (16). There are a number of variants of exon I. These encode the 5′-untranslated regions of various aromatase mRNAs, which are selectively expressed in some tissues by alternative splicing (16, 43, 44). The tissue-specific expression of aromatase in humans appears to be mediated by tis-

A

Relative LUC activity

□ 0 nM ▨ 10 nM
■ 1 nM ■ 100 nM

pSVSPORT1	-	-	-	-	+	+	+	+
pSVhRXRα	+	+	+	+	-	-	-	-
9cRA	+	-	-	-	+	-	-	-
LG100268	-	+	-	-	-	+	-	-
TBTCl	-	-	+	-	-	-	+	-
TPTOH	-	-	-	+	-	-	-	+

B

Relative LUC activity

NS

control atRA 9cRA LG100268 TBTCl TPTOH

□ RXR(-) / RAR(-)   ▨ RXR(-) / RAR(+)
■ RXR(+) / RAR(-)   ■ RXR(+) / RAR(+)

Fig. 9. Ability of TBTCl and TPTOH to Increase Transcription of an LUC Reporter Gene Containing the Human Placental Promoter I.1 Sequence of Aromatase via the Activation of RXR but not RAR

A, JEG-3 cells were cotransfected with 10 ng of either pS-VhRXRα or pSVSPORT1 in addition to 50 ng PGVArom and then treated with various concentrations of 9cRA, LG100268, TBTCl, or TPTOH. B, JEG-3 cells were cotransfected with 10 ng pSVhRXRα or pSV40hRARβ, or both, in addition to 50 ng PG-VArom, and then treated with 100 nM of atRA, 9cRA, LG100268, TBTCl, or TPTOH. pRL-TK (2 ng) was cotransfected as the control for normalization (see *Materials and Methods*). The results were expressed as average fold activation ± 1 SD after normalization to *Renilla* LUC activity. *, $P < 0.05$; **, $P < 0.01$; and ***, $P < 0.005$. NS, Not significant ($P \geq 0.05$).

sue-specific promoters lying upstream of the respective exon I sequences and by the binding of transcription factors to specific regions of each promoter. In the placenta, aromatase is driven by the placental major promoter (I.1), and the transcript contains exon I.1. In contrast to our results, Saitoh *et al.* (47) recently reported that TBT inhibits aromatase activity and decreases mRNA levels in ovarian granulosa cells. They also suggested that TBT-induced suppression of aromatase in the cells is partly regulated at the transcriptional level because of association with the cAMP-protein kinase A pathway or regulation by the steroidogenic tissue-specific transcriptional factor adrenal 4 binding protein/steroidogenic factor 1. In con-

trast to those in the placenta, ovarian transcripts of aromatase contain a 5' sequence immediately upstream of the translation start site, because expression of the gene in the ovary uses a proximal promoter (II) that is strongly regulated by adrenal 4 binding protein/steroidogenic factor 1 and cAMP. In addition, RXR and PPARγ ligands suppress the mRNA expression of aromatase in ovarian granulosa cells (48, 49). Therefore, in light of our findings, TBT-induced suppression of aromatase in ovarian granulosa cells may involve RXR activation.

The RXRs stand out as unique members of the type II nuclear receptor subfamily and play a dual role in nuclear receptor signaling. On one hand, they can bind to their own response element (DR1) as a homodimer and activate transcription in response to their ligands, and, on the other hand, they serve as partners for other nuclear receptors (1–3). Trialkyltin compounds bind to RXRs to induce their transcription. In turn, the expression of hCG and aromatase induced by these compounds may involve either RXR-homodimer or -heterodimer, or both. The existence of three types of heterodimers—nonpermissive, conditionally permissive, and fully permissive—has been described. Nonpermissive heterodimers include RXR-TR and RXR-VDR, which cannot be activated by RXR agonist regardless of the presence (or absence) of the agonist of its partner receptor; formation of the heterodimer is thought to preclude the binding of ligand to RXR (50, 51). RXR-ligand-dependent transcription in promoter I.1 of human aromatase is reported to be regulated by RXR-VDR heterodimers, owing to binding to the imperfect palindromic sequence located from −183 to −172 bp upstream of the transcriptional start site (13). However, within these complexes, RXR acts as a silent partner, as described earlier (50). In addition, we used a GAL-VDR chimeric receptor to confirm that TBT and TPT could not activate transcription of VDR (data not shown). Consequently, both alkyltin-induced aromatase activity and mRNA expression may not involve the association of RXR-VDR. Although RXR-TR heterodimer generally is believed to be nonpermissive (51), Castillo *et al.* (52) recently demonstrated that RXR-TR heterodimer can function as a permissive heterodimer to allow 9cRA-induced stimulation of prolactin gene transcription in rat pituitary cells. Accordingly, we used a synthetic DR4 reporter gene to examine whether TBTCl and TPTOH stimulate transcription of RXR-TR heterodimer. However, these trialkyltin compounds had no effect on transactivation of these complexes in the presence or absence of T_3. We then used a GAL-TR chimeric receptor to confirm that TBT and TPT could not activate transcription of TR (data not shown). These results suggest that these trialkyltin-induced transcriptional activities also do not involve the association of RXR-TR.

As an example of the second type of heterodimer, the RXR-RAR heterodimer exhibits conditional permissivity because full response to RXR agonist occurs only in the presence of an RAR agonist (38, 41). Our

results showed TBT and TPT function as RXR agonists but not RAR agonist. Although RXR-RAR heterodimer generally is believed to be nonpermissive in the absence of RAR agonist, LG100754, which binds to RXRs but not RARs, strongly transactivates this heterodimer pair (53). In addition, the mRNA expression of both hCG and aromatase is also induced by RAR-specific agonist (Fig. 4), and it is possible that in light of the result in Fig. 9B, the transcription from promoter I.1 of human aromatase may be regulated by RXR-RAR heterodimers. However, TBTCl and TPTOH failed to transactivate RXR-RAR heterodimer on either RAR response element (DR2 and DR5) reporter elements or promoter I.1 elements of human aromatase (Figs. 5B and 9B). These results suggest that, unlike the effect of LG100754, these trialkyltin-induced transcriptional activities do not involve the association of RXR-RAR.

The third type is the permissive heterodimers, such as PPAR-RXR and FXR-RXR, which exhibit dual ligand permissivity, because they can be activated by the agonists of either RXR or its partner receptor, or both, in a more-than-additive fashion (35–40). The PPAR ligand 15dPGJ$_2$, PPARγ-specific ligand rosiglitazone, and FXR ligand CDCA all failed to increase mRNA expression of aromatase in Jar cells (Fig. 4B), suggesting that neither PPAR-RXR nor FXR-RXR heterodimers are involved in organotin-induced aromatase expression in the human placenta and that RXR homodimer may be required for organotin-induced aromatase expression. By contrast, PPAR agonists, in addition to RXR and RAR agonists, stimulate mRNA expression of hCGβ, as previously described (Fig. 4 and Refs. 9, 10, 12, and 14). These findings indicate that organotin-induced hCGβ expression might involve either PPAR-RXR heterodimers or RXR homodimer.

To address these possibilities, we constructed a LUC reporter plasmid containing the promoter sequence (−455 to +365 bp) of hCGβ5, which is the predominant hCGβ subunit expressed in the human placenta, and assessed the effectiveness of TBTCl and TPTOH in stimulating LUC activity by using JEG-3 cells cotransfected with a human RXRα expression plasmid and the hCGβ5-LUC reporter plasmid. However, trialkyltin compounds, RXR, and PPAR ligands failed to stimulate LUC expression (data not shown), whereas cAMP analogs stimulated gene expression, as previously described (45). Furthermore, Tarrade et al. (14) reported that ligand-dependent mRNA expression of hCGβ is transcriptionally controlled by PPARγ-RXR heterodimers, which bind to DR1 as well as does RXR homodimer. However, like us, they failed to detect expression of reporter gene constructs containing imperfect DR1 motifs in the regulatory region of the hCGβ gene. Transcriptional regulation in promoter I.1 of human aromatase and the hCGβ promoter is not yet fully understood, and neither the PPAR response element nor the RXRE involved in both promoter activation by RXR ligands has been identified. Further studies are needed to clarify the precise mechanism of action of RXRs in the expression of human placental

aromatase and hCG, because the ligand-dependent signaling pathways of RXRs appear intricate.

We assayed 15 tin compounds, in addition to TBTCl and TPTOH, for their ability not only to induce hCG production, aromatase activity, and mRNA expression of both factors but also to activate RXR through binding to the LBD of the receptor. hCG production and aromatase activity did not differ significantly among the TBT and TPT derivatives. In addition, the abilities to bind to the LBD of RXR and activate the receptor were similar among these compounds, because they all competed with both [³H]9cRA and [¹⁴C]TPTOH for binding to RXR approximately as well as did TBTCl and TPTOH. These results suggest that the exact identity of the ligand on the trialkyltin (as long as it is not another alkyl group) is relatively unimportant for binding to RXR.

By contrast, approximately 50- to 100-fold higher concentrations of tetraalkyltin compounds such as TeBT and TBVT were needed to elicit a response, compared with those of the TBT and TPT derivatives. In addition, although the tetraalkyltin compounds stimulated transcription through RXR, they hardly competed with [³H]9cRA for binding to the LBD of RXR. This observation may indicate that the tetraalkyltin compounds were metabolically converted to the active form in the cells. This hypothesis is supported by the general trend of the previous results showing that organotin compounds undergo dealkylation by the microsomal monooxygenase system, which is dependent on cytochrome P450 in the liver and other organs (54–56). The presence of a fourth alkyl group on the tin atom may interfere with the binding of alkyltin compounds to RXR, and activation of the receptor by these tetraalkyltin compounds may be the result of their metabolic conversion in cells to the active dealkylated form (e.g. TBT). Such events are reminiscent of an early observation that atRA could activate RXR in cells because of its metabolic conversion to the high-affinity ligand 9cRA (57). Although the dialkyltin compounds neither bind to nor activate RXR, DBTCl$_2$ and DPTCl$_2$ induced expression of the mRNA of aromatase and hCGβ, respectively. It remains unclear why these dialkyltin compounds induced expression of the mRNA of aromatase or hCGβ, but the induction appears to be caused by a mechanism other than activation of RXRs.

Among the trialkyltin compounds other than TBT and TPT derivatives, TPrTCl was most active. TPrTCl activated transcription of RXR as well as did 9cRA and, like TBTCl and TPTOH, completely out competed both [³H]9cRA and [¹⁴C]TPTOH for binding to RXR. TETBr bound weakly to RXR, but we were unable to detect TETBr-induced transcription of RXR and mRNA expression of hCGβ and aromatase. The fact that TETBr is cytotoxic at concentrations greater than 300 nM, according to the result of the [³H]thymidine uptake assay (data not shown), may render TETBr-stimulated RXR activation undetectable. TChTOH, which activated transcription of RXR, completely out competes [¹⁴C]TPTOH for binding to the LBD of RXR, whereas it

cannot out compete [^{3}H]9cRA at all. This difference in the ability of TChTOH to compete with [^{3}H]9cRA and [^{14}C]TPTOH may be caused by differences in their ligand-protein contacts (see following paragraph). These results suggest that the affinity of tin compounds to RXR is related to both the numbers and lengths of their alkyl groups.

RXR has been characterized as a nuclear receptor that demonstrates a highly restricted substrate specificity. Until recently, 9cRA was defined as the most potent RXR activator. However, various fatty acids, such as docosahexaenoic acid (DHA) and phytanic acid, and methoprene acid, a synthetic juvenile hormone analog used as an insect regulator, have been identified as RXR ligands (58–62). In addition, several retinoids with RXR selectivity have been developed (63), because retinoids are important therapeutic agents in the treatment of cancer and proliferative diseases of the skin. Although fatty acid- or methoprene acid-induced RXR activation requires greater than 1000-fold higher concentrations than that induced by 9cRA (58–62), the protein-ligand interactions of almost all RXR ligands share several common characteristics. Recently, Egea *et al.* (64) have obtained some interesting findings through analyzing the crystal structures of RXR with DHA, the synthetic ligand BMS649, and 9cRA. For example, RXR ligands contain a carboxylate group, which is important in their ability to be buried stably in the predominantly hydrophobic pocket. This functional group is involved in an ionic interaction with the strictly conserved basic residue R316 of helix H5 and forms a hydrogen bond with the backbone carbonyl amide group of the β-turn residue A327. Furthermore, ligand atoms C14–C22 of DHA and the tetrahydrotetramethylnaptho group of BMS649 occupy the same hydrophobic cavity (delineated by helices H3, H7, and H11), in which the β-ionone ring of 9cRA is buried stably. However, although trialkyltin compounds bind RXR with high specificity and induce RXR activation at doses similar to those of 9cRA, they lack a carboxylate group. Further, except for the TPT derivatives and TChTOH, RXR-stimulating trialkyltin compounds also lack sufficiently long fatty acid and cyclic functional groups, both of which might be buried in the β-ionone binding subpocket. In the competitive ligand-binding assay, RXR-stimulating trialkyltin compounds, except for TChTOH, completely out competed both [^{3}H]9cRA and [^{14}C]TPTOH, whereas 9cRA could not completely out-compete [^{14}C]TPTOH for binding to RXR. In addition, TChTOH out competed [^{14}C]TPTOH but not [^{3}H]9cRA. Together, these results suggest that the protein-ligand interaction of trialkyltin compounds and RXR is very different from those seen with other RXR ligands. Indeed, previous studies have reported that, despite the overall similarity of protein-ligand interactions, RXR ligands differ, especially within the L-shaped binding pocket. Although further studies are necessary to clarify which amino acid of RXR is important to the binding of trialkyltin compounds to the ligand-binding pocket,

the ligand-protein contacts of these trialkyltin compounds are probably unique to them.

To our knowledge, ours is the first study to clarify the molecular mechanism of trialkyltin-induced endocrine-disrupting effects in the human placenta. Through RXR activation, trialkyltin compounds may be potent endocrine disruptors of other human tissues, because these compounds alter the endocrine functions, differentiation, and other processes of several human cell types (21, 47, 65–67). Furthermore, we demonstrated that trialkyltin compounds function as RXR ligands with novel structures, which bind to the LBD of RXR with high affinity and stimulate transcription of the receptor. We believe that our results provide information useful in the design of novel RXR ligands.

MATERIALS AND METHODS

Chemicals and Cell Culture

TBTCl, TPTOH, TOTH, and DBTCl$_2$ were obtained from To-kyo Kasei Kougyo (Tokyo, Japan). SnCl$_4$, TMTCl, TETBr, TChTOH, MBTCl$_3$, MPTCl$_3$, DPTCl$_2$, TPTCl, TBTH, TBTBr, TeBT, and TBVT were obtained from Aldrich Chemicals (Milwaukee, WI). 9cRA, atRA, AM580, and CDCA were obtained from Sigma Chemical Co. (St. Louis, MO). 15dPGJ$_2$ and rosiglitazone were obtained from Cayman Chemical (Ann Arbor, MI). TPrTCl was obtained from Merck (Darmstadt, Germany). LG100268 (>95% pure) was synthesized in the Medical Chemistry Laboratories of Fujisawa Pharmaceutical (Osaka, Japan). Human choriocarcinoma cell lines Jar and JEG-3 were obtained from American Type Culture Collection (ATCC; Manassas, VA). Jar cells (ATCC No. HTB-144) were cultured in RPMI 1640 medium with 2 mM L-glutamine, 1 mM pyruvate, 4.5 g/liter glucose, and 10% fetal calf serum (FCS). JEG-3 cells (ATCC no. HTB-36) were cultured in MEM with 2 mM L-glutamine, 0.1 mM MEM nonessential amino acid solution (Invitrogen, Carlsbad, CA), and 10% FCS. To determine the effect of tin compounds on hCG secretion, aromatase activity, and mRNA expression of Jar cells, the cells were seeded and precultured for 24 h and then treated with either various concentrations of tin compounds in 0.1% dimethyl sulfoxide (DMSO) or vehicle alone (0.1% DMSO) for an additional 24 or 48 h. In control experiments, 0.1% DMSO did not alter hCG secretion, aromatase activity, mRNA expression of hCGβ and aromatase, or the results of reporter gene assays in any of the cell lines examined.

Determination of hCG Production in Culture Media

hCG production was assessed as previously described (27). Jar cells were seeded in 48-well plates (4 × 10^4 cells per well) in regular culture medium supplemented with 5% charcoal-stripped FCS instead of 10% normal FCS. After 24 h, cells were treated with various tin compounds for 48 h. To determine hCG production, the cells were then washed and cultured in fresh medium for another 24 h. Culture supernatant was collected, and hCG concentration was determined by ELISA. Microtiter ELISA plates were coated with 5 μg/ml rabbit polyclonal antibody against intact hCG in 0.05 M sodium bicarbonate, 0.02 M sodium carbonate buffer (pH 9.6) overnight at 4 C. They were blocked for 2 h at room temperature with 1% (wt/vol) gelatin in PBS, washed with 0.05% (vol/vol) Tween 20 in PBS (TPBS), and incubated for 2 h at 37 C with 50 μl collected test samples. After being washed three times with TPBS, the plates then were incubated for 2 h at 37

C with 1:1000 mouse monoclonal antibody against the β-subunit of hCG. After being washed with TPBS, the plates were incubated for an additional 2 h at 37 C with 1:1000 rabbit antimouse IgG1 antibody conjugated with horseradish peroxidase (Zymed Laboratories, Inc., South San Francisco, CA). The plates then were washed with TPBS and developed using 2.5 mM 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (Sigma) in 0.1 M citrate buffered solution containing 0.015% H_2O_2. The reaction was stopped by the addition of 0.1% NaN_3, after which the plates were read at a wavelength of 415 nm in a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA). The level of hCG in the culture supernatant was calculated from a standard curve by using Microplate Manager III software (Bio-Rad). The standardized hCG was a kind gift from Teikoku Hormone Manufacturing (Tokyo, Japan).

Aromatase Assay

Aromatase activity was determined as previously described (27). Jar cells were seeded in 12-well plates (1.5×10^5 cells per well) in regular culture medium supplemented with 5% charcoal-stripped FCS instead of 10% normal FCS. After 24 h, cells were treated with various tin compounds for 48 h. At the end of each treatment, cells were washed three times with PBS. Aromatase activity then was determined by tritium release assay. This method measures production of ^3H_2O, which forms as a result of aromatization of the substrate [1β-^{3}H]androst-4-ene-3,17-dione (New England Nuclear, Boston, MA). Serum-free medium containing [1β-^{3}H]androst-4-ene-3,17-dione solution (54 nM) was prepared, and 0.5 ml of this solution was added to each well. In addition, wells containing media alone were tested to provide control values for aromatase activity. After incubation for 1 h, each plate was placed on ice, and 200 μl of culture medium was withdrawn from each well. The medium was extracted with 500 μl chloroform, vortexed, and then centrifuged for 1 min at 9000 $\times$ g. A 100-μl aliquot of the aqueous phase was mixed with 100 μl of a 5% wt/vol charcoal 0.5% wt/vol dextran T-70 suspension, vortexed, and then incubated for 10 min. After centrifugation of the solution for 5 min at 9000 $\times$ g, a 150-μl aliquot was removed to measure the level of radioactivity by liquid scintillation.

Quantitative RT-PCR

Jar cells were seeded in 100-mm tissue culture plates (1×10^6 cells) and treated with various compounds in regular culture medium supplemented with 5% charcoal-stripped FCS instead of 10% normal FCS, after which total RNA was extracted from them using TRIzol reagent (Invitrogen). mRNA expression of hCGβ and aromatase in Jar cells was determined by quantitative RT-PCR, as previously described (27). Total RNA (5 μg) extracted from Jar cells was reverse transcribed using SuperScript II reagent (Invitrogen) and oligo-(dT) as primer. The reaction was performed by incubation for 1 h at 42 C. After termination of cDNA synthesis, reaction mixtures were diluted with 4 volumes of Tris-EDTA. Aliquots (2 μl) of diluted reverse transcribed products were amplified in a reaction mixture containing 2× buffer from the Quanti-Tect SYBR Green PCR kit (QIAGEN, Valencia, CA) and 0.5 μM of each primer by using LightCycler (Roche Diagnostics, Mannheim, Germany). After preincubation at 95 C for 15 min, PCR was performed with 35–40 cycles of denaturation at 95 C for 15 sec, annealing at 65 C for 30 sec, and elongation at 72 C for 10 sec. Primers used were as follows: human aromatase, 5'-CCGGCCTTGTTCGTATGGTCA-3' and 5'-CAA-CACGTCCACATAGCCCGA-3'; hCGβ, 5'-CCGTGTGCATC-ACCGTCAACA-3' and 5'-GTTCGCACACCACCTGAGGCAG-3'; and human β-actin, 5'-CTACGAGCTGCCTGACGGC-3' and 5'-GCCACAGGACTCCATGCCC-3'.

Plasmid Construction

Human RXRα and RARβ cDNAs were amplified by RT-PCR using total RNA from JEG-3 cells. The amplified RXRα fragment was cloned into pSVSPORT1 (Invitrogen), whereas the RARβ fragment was cloned into a simian virus 40 promotor-containing expression vector. The resulting RXRα and RARβ expression vectors were termed pSVhRXRα and pSV40hRARβ, respectively. A 2.4-kb promoter I.1 sequence of the human aromatase gene (−2295 to +107 bp) was PCR amplified from JEG-3 genomic DNA. KpnI and SmaI sites were introduced into the 5'- and 3'-termini, respectively, of the amplified fragment, which then was subcloned into the KpnI–SmaI site of PGVB2 (Nippon Gene, Tokyo, Japan); the resulting reporter construct was termed PGVArom.

To construct a reporter plasmid containing an RXRE and RAR response element, response elements were cloned into the SmaI site of pTAL-Luc (CLONTECH Laboratories, Inc., Palo Alto, CA); response elements with the underlined consensus hexanucleotide sequence were as follows: DR1 × 2 (5'-AGGTCA a AGGTCA a AGGTCA a AGGTCA-3'); DR2 × 2 (5'- aa AGGTCA aa AGGTCA ccatcccgggaaa AGGTCA aa AGGTCA cc-3'); DR5 × 2 (5'-aa AGGTCA ccgaa AGGTCA ccatcccgggaaa AGGTCA ccgaa AGGTCA cc-3'); the resulting reporter constructs were termed pTALDR1, pTALDR2, and pTALDR5, respectively. The LBDs of hRXRα (codons 201–693), hRXRβ (codons 275–534), and hRXRγ (codons 172–455) were amplified by RT-PCR using mRNA from human liver and kidney and subcloned into pGEX-4T (Amersham Biosciences, Piscataway, NJ). These constructs were used for generation of glutathione S-transferase (GST)-hRXR fusion proteins. For chimeric receptor assay, the LBD of hRXRα was fused to the C-terminal end of GAL4-DNA binding domain (amino acids 1–147) in the pBK-CMV expression vector (Stratagene, La Jolla, CA) to yield pBK-CMV-GAL4-hRXRα. All sequences synthesized by PCR were confirmed by DNA sequencing. The plasmid p4×UAS-tk-luc, a LUC reporter construct containing four copies of the GAL4 binding site [upstream activating sequence (UAS) of GAL1] followed by a thymidine kinase promoter, was a kind gift from Dr. Y. Kamei (National Institute of Health and Nutrition, Japan).

Transient Transfection Assay

Transfection was performed with Lipofectamine regent (Invitrogen) in accordance with the manufacturer's instructions. JEG-3 cells (3×10^4 cells) were seeded in 24-well plates 24 h before transfection with the optimal dose of each DNA construct. At 18 h after transfection, various compounds were added to the transfected cells, which were then cultured in regular culture medium supplemented with 1% charcoal-stripped FCS instead of 10% normal FCS. The cells were harvested 30 h later, and extracts were prepared and assayed for LUC activity by using the dual-LUC reporter assay system (Promega Corp., Madison, WI) in accordance with the manufacturer's instructions. To normalize LUC activity for transfection and harvesting efficiency, the Renilla LUC control reporter construct pRL-TK (Promega) was cotransfected as an internal standard in all reporter experiments. The results are expressed as the average relative LUC activity of at least quadruplicate samples.

Ligand Binding Assay

The GST-RXR fusions were expressed in Escherichia coli DH5α cells and purified according to the manufacturer's (Amersham Biosciences) instructions. The purified proteins (30 μg/ml) were incubated with increasing concentrations of either [^{3}H]9cRA (1.63 tBq/mmol, Amersham Biosciences) or [^{14}C]TPTOH (2.04 gBq/mmol, Amersham Biosciences) with or without a 100-fold molar excess of each unlabeled compound. After incubation at 4 C for 1 h, specific binding was

determined by hydroxyapatite binding assay as described elsewhere (68). Binding in the presence of a 100-fold molar excess of unlabeled ligand was defined as nonspecific binding; specific binding was defined as total binding minus nonspecific binding. Similarly, tin compounds were used to compete for [^{3}H]9cRA and [^{14}C]TPTOH in this assay to determine the binding preferences of RXRs.

Statistics

Data were analyzed by the two-tailed unpaired Student's *t* test by using SPSS software (SPSS, Inc., Chicago, IL). Control and treatment group data were always obtained from equal numbers of replicate experiments. Values with $P < 0.05$ were considered statistically significant.

Acknowledgments

REFERENCES

1. Chambon P 1996 A decade of molecular biology of retinoic acid receptors. FASEB J 10:940–954
2. Aranda A, Pascual A 2001 Nuclear hormone receptors and gene expression. Physiol Rev 81:1269–1304
3. Giguere V 1994 Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr Rev 15:61–79
4. Sapin V, Ward SJ, Bronner S, Chambon P, Dolle P 1997 Differential expression of transcripts encoding retinoid binding proteins and retinoic acid receptors during placentation of the mouse. Dev Dyn 208: 199–210
5. Sapin V, Dolle P, Hindelang C, Kastner P, Chambon P 1997 Defects of the chorioallantoic placenta in mouse RXRα null fetuses. Dev Biol 191:29–41
6. Wendling O, Chambon P, Mark M 1999 Retinoid X receptors are essential for early mouse development and placentogenesis. Proc Natl Acad Sci USA 96: 547–551
7. Mascrez B, Mark M, Krezel W, Dupe V, LeMeur M, Ghyselinck NB, Chambon P 2001 Differential contributions of AF-1 and AF-2 activities to the developmental functions of RXRα. Development 128:2049–2062
8. Noback CR, Takahashi YI 1978 Micromorphology of the placenta of rats reared on marginal vitamin-A-deficient diet. Acta Anat (Basel) 102:195–202
9. Guibourdenche J, Alsat E, Soncin F, Rochette-Egly C, Evain-Brion D 1998 Retinoid receptors expression in human term placenta: involvement of RXRα in retinoid induced-hCG secretion. J Clin Endocrinol Metab 83: 1384–1387
10. Guibourdenche J, Roulier S, Rochette-Egly C, Evain-Brion D 1998 High retinoid X receptor expression in JEG-3 choriocarcinoma cells: involvement in cell function modulation by retinoids. J Cell Physiol 176: 595–601
11. Roulier S, Rochette-Egly C, Rebut-Bonneton C, Porquet D, Evain-Brion D 1994 Nuclear retinoic acid receptor characterization in cultured human trophoblast cells: effect of retinoic acid on epidermal growth factor receptor expression. Mol Cell Endocrinol 105:165–173
12. Matsuo H, Strauss III JF 1994 Peroxisome proliferators and retinoids affect JEG-3 choriocarcinoma cell function. Endocrinology 135:1135–1145
13. Sun T, Zhao Y, Mangelsdorf DJ, Simpson ER 1998 Characterization of a region upstream of exon I. 1 of the human CYP19 (aromatase) gene that mediates regulation by retinoids in human choriocarcinoma cells. Endocrinology 139:1684–1691
14. Tarrade A, Schoonjans K, Guibourdenche J, Bidart JM, Vidaud M, Auwerx J, Rochette-Egly C, Evain-Brion D 2001 PPARγ/RXRα heterodimers are involved in human CGβ synthesis and human trophoblast differentiation. Endocrinology 142:4504–4514
15. Zhu SJ, Li Y, Li H, Wang YL, Xiao ZJ, Vihko P, Piao YS 2002 Retinoic acids promote the action of aromatase and 17β-hydroxysteroid dehydrogenase type 1 on the biosynthesis of 17β-estradiol in placental cells. J Endocrinol 172:31–43
16. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendelson CR, Bulun SE 1994 Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15: 342–355
17. Albrecht ED, Pepe GJ 1990 Placental steroid hormone biosynthesis in primate pregnancy. Endocr Rev 11: 124–150
18. Shozu M, Akasofu K, Harada T, Kubota Y 1991 A new cause of female pseudohermaphroditism: placental aromatase deficiency. J Clin Endocrinol Metab 72: 560–566
19. Yoshimi T, Strott CA, Marshall JR, Lipsett MB 1969 Corpus luteum function in early pregnancy. J Clin Endocrinol Metab 29:225–230
20. Huhtaniemi IT, Korenbrot CC, Jaffe RB 1977 hCG binding and stimulation of testosterone biosynthesis in the human fetal testis. J Clin Endocrinol Metab 44: 963–967
21. Boyer IJ 1989 Toxicity of dibutyltin, tributyltin and other organotin compounds to humans and to experimental animals. Toxicology 55:253–298
22. Fent K 1996 Ecotoxicology of organotin compounds. Crit Rev Toxicol 26:1–117
23. Horiguchi T, Shiraishi H, Shimizu M, Morita M 1997 Effects of triphenyltin chloride and five other organotin compounds on the development of imposex in the rock shell, *Thais clavigera*. Environ Pollut 95:85–91
24. Matthiessen P, Gibbs PE 1998 Critical appraisal of the evidence for tributyltin-mediated endocrine disruption in mollusks. Environ Toxicol Chem 17:37–43
25. Kannan K, Tanabe S, Iwata H, Tatsukawa R 1995 Butyltins in muscle and liver of fish collected from certain Asian and Oceanian countries. Environ Pollut 90:279–290
26. Kannan K, Tanabe S, Tatsukawa R 1995 Occurrence of butyltin residues in certain foodstuffs. Bull Environ Contam Toxicol 55:510–516